499 studies found for:    "Lupus Erythematosus, Systemic"
Show Display Options
Rank Status Study
21 Completed Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Biological: Prevenar® and Pneumo23®;   Biological: Placebo, Pneumo23®
22 Completed Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
Conditions: Immune System Diseases;   Autoimmune Diseases;   Lupus Erythematosus, Systemic;   Skin and Connective Tissue Diseases;   Connective Tissue Disease
Interventions: Biological: CDP7657;   Other: Placebo
23 Completed
Has Results
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Atacicept 75 mg;   Drug: Atacicept 150 mg;   Other: Placebo Comparator
24 Completed Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
Conditions: Lupus Erythematosus, Systemic;   Adverse Effects
Interventions: Genetic: Polymorphism Analysis;   Drug: Cyclophosphamide;   Other: Pharmacokinetic analysis
25 Not yet recruiting TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: TAB08;   Other: Placebo
26 Completed
Has Results
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Rituximab;   Drug: Placebo;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine
27 Terminated
Has Results
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Rituximab;   Drug: Methylprednisolone;   Drug: Acetaminophen;   Drug: Diphenhydramine
28 Completed
Has Results
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
29 Recruiting A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Biological: ALX-0061;   Biological: Placebo
30 Recruiting A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: IPP-201101;   Drug: Placebo;   Other: Standard of Care
31 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
32 Recruiting Study of Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention:
33 Completed A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
Condition: Systemic Lupus Erythematosus
Intervention: Drug: A-623
34 Completed Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Other: Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
35 Completed PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: A-623;   Other: Placebo Comparator
36 Active, not recruiting CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: blisibimod;   Drug: Placebo
37 Unknown  Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)
Condition: Refractory Systemic Lupus Erythematosus
Intervention: Biological: Allogeneic MSC (AlloMSC)
38 Completed Anti-ficolin-3 Autoantibodies in Lupus Nephritis
Condition: Lupus Erythematosus, Systemic
Intervention: Other: Biological analysis
39 Recruiting CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Blisibimod;   Drug: Placebo
40 Withdrawn CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Blisibimod;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years